Edward Kaye was Appointed as President and Chief Executive Officer at Stoke Therapeutics

Date of management change: October 14, 2017 

What Happened?

Bedford, MA-based Stoke Therapeutics Appointed Edward Kaye as President and Chief Executive Officer

 

About the Company

Stoke Therapeutics is pioneering a new way to treat the underlying causes of severe #geneticdiseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. At Stoke, we believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or #TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. We have identified approximately 2,900 genetic diseases which we believe may be amenable to TANGO. At Stoke, we are united around a common goal: to improve the lives of people living with severe genetic diseases. Stoke is located in Bedford, MA with offices in Cambridge, MA.

 

About the Person

Edward Kaye is President and Chief Executive Officer at Stoke Therapeutics. Previously, Edward held various senior HR leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Horan Annmarie, Jourdan Gregory, Purcell Stan, Raman Pradheepa, Blank Dayna, Smith Chris, Schroeder Kellie, Ko Kei-Yu, Ezell Bob, Gonzalez Mark, Van Ackeren Zena

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.